Share Name Share Symbol Market Type Share ISIN Share Description
Indivior LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.40p -0.88% 271.30p 271.00p 271.30p 276.00p 270.00p 271.20p 2,262,161 16:35:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 809.2 101.4 5.9 43.1 1,975.90

Indivior Share Discussion Threads

Showing 501 to 521 of 525 messages
Chat Pages: 21  20  19  18  17  16  15  14  13  12  11  10  Older
DateSubjectAuthorDiscuss
09/8/2018
10:32
RNS: Standard Life upping their stake to 7.09%...
7ran5ac710n
31/7/2018
13:45
Indivior (INDV) News Out Just Now http://crweworld.com/article/news-provided-by-pr-newswire/755185/indivior-preliminary-injunction-on-generic-buprenorphine-and-naloxone-sublingual-film-upheld
danieldanj
31/7/2018
09:59
Yes this is better news. I found yesterday's legal ruling, allowing Dr Redy's to expedite the hearing, was no surprise to certain legal professionals with one opinion stating there was no legal reason not to. That decision cast no view on the validity or otherwise of Indivior's patents. This latest ruling appears to be much more about upholding the validity of Indivior's patents, until proved otherwise, in a future Court hearing.
gregmorg
31/7/2018
09:12
31 July 2018 Indivior Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Upheld -Company will continue to vigorously defend our SUBOXONE(R) (buprenorphine and naloxone) Sublingual Film intellectual property - Slough, UK, 31 July 2018 - Indivior PLC (LON: INDV) (Indivior or the Company) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied Dr. Reddy's Laboratories' (DRL's) motion for a stay of the July 13, 2018 preliminary injunction (PI) previously granted by the District of New Jersey. The PI prohibits DRL from using, importing, selling, or offering to sell its generic buprenorphine/naloxone sublingual film product. DRL appealed this ruling, and filed emergency motions seeking to expedite the appeal of the PI, and to stay the PI pending a ruling on appeal. Today's ruling means that DRL continues to be prohibited from using, importing, selling, or offering to sell its generic buprenorphine/naloxone sublingual film product pending a favorable outcome for DRL on its appeal of the PI, or the District of New Jersey litigation related to U.S. Patent No. 9,931,305 (the '305 Patent); 9,687,454 (the '454 Patent); and 9,855,221 (the '221 Patent). The CAFC previously granted DRL's motion to expedite the appeal, and oral argument will be held the first week of October 2018. Indivior will continue to vigorously defend its patent rights to SUBOXONE(R)Film, including opposing DRL's PI appeal, and continuing to pursue the appeal of the District of Delaware's noninfringement ruling related to U.S. Patent No. 8,603,514 (the '514 Patent), and the recently filed litigation asserting the '305, '454, and '221 Patents in the District of New Jersey.
grupo guitarlumber
31/7/2018
09:11
SURPRISED TOO, NO UPWARD MOMENTUM PERHAPS ITS DUE TO END OF MONTH
grupo guitarlumber
31/7/2018
08:46
Surprised by lack of movement today
tsmith2
30/7/2018
09:50
The Dr Redy decision to expedite the Court hearing is, of course, purely legal. It has little to do with, and making no observations on, the actual validity of the Indivior patents..
gregmorg
30/7/2018
08:58
Oliver Haill WebFG News 30 Jul, 2018 08:10 30 Jul, 2018 08:10 Indivior given October court date with Dr Reddy's, delays Perseris launch Indivior 318.40 08:39:28 30/07/18 1.08% 3.40 FTSE 250 20,843.16 08:40:20 30/07/18 -0.12% -25.78 FTSE 350 4,277.69 08:40:20 30/07/18 -0.25% -10.91 FTSE All-Share 4,222.12 08:40:18 30/07/18 -0.25% -10.52 Indivior's lawyers will be able to begin arguing the drug developer's case against Dr Reddy Laboratories in October, after the US appeals court agreed to speed up the process. The FTSE 250-listed company also on Monday confirmed that its once-monthly treatment for schizophrenia in adults has been approved by the US drug regulator, but that it would delay the timing of the launch until it knew more about the Dr Reddy's case. Dr Reddy's launched an appeal after Indivior was granted a preliminary injunction that prevented the generic drugmaker from selling its version of Indivior's Suboxone, a buprenorphine/naloxone sublingual film that is used as a treatment for opioid addiction. The US Court of Appeals for the Federal Circuit has now granted-in-part a motion to expedite Dr Reddy's appeal of the preliminary injunction that prohibits its from using, importing, selling, or offering to sell its generic sublingual film, meaning oral argument are scheduled to be held during the first week of October. Dr Reddy's appeal also requested a stay of the injunction but the CAFC has not yet ruled on this. Although the US Food & Drug Administration over the weekend approved Perseris, a once-monthly injection to treat adult schizophrenia, Indivior said that, as it had indicated in its half-year results last week, it will hold back from launching this new treatment due to the uncertainty over the Dr Reddy's generic. The company assured that would provide details of the "appropriate launch timing" for Perseris "as soon as reasonably practicable, but no later than its Q3 2018 results currently scheduled for November 1st". Perseris contains risperidone, which is a well-established treatment for schizophrenia, but has been formulated by Indivior into an extended-release 'depot' delivery system that is delivered subcutaneously and remains sustained levels over the course of the month.
waldron
30/7/2018
08:08
Seems like it.expecting them to move up..
tsmith2
30/7/2018
07:32
"Motion to Expedite DRL's Appeal of Indivior's Preliminary Injunction Granted-in-Part"An offset to the approval of Perseris.Market makers could be in a quandary as how to open this one up.
steeplejack
29/7/2018
21:51
Depends on the whether the court dismisses the Dr Reddy appeal to lift the preliminary injunction. The company must be chuffed that it now has a drug that doesn't have generics breathing down its neck
steeplejack
29/7/2018
20:01
£3.5 open?
tsmith2
28/7/2018
14:16
Yes,Indeed good product news. So we expect an RNS first thing Monday
gregmorg
28/7/2018
12:01
http://uk.advfn.com/cmn/fbb/thread.php3?id=41714980
florenceorbis
28/7/2018
08:10
http://www.indivior.com/investor-news/fda-approves-perseris-risperidone-extended-release-injectable-suspension-treatment-schizophrenia-adults/nice...
tsmith2
28/7/2018
03:28
Indivior (INDV) News Out Just Now http://crweworld.com/article/news-provided-by-pr-newswire/752563/fda-approves-perseris-risperidone-for-extended-release-injectable-suspension-for-the-treatment-of-schizophrenia-in-adults
danieldanj
27/7/2018
15:24
FDA could give us a shot in the arm
tsmith2
26/7/2018
15:30
Piled in on 25th - Vampire Squid should've waited too before upping their stake to 16%...?
7ran5ac710n
26/7/2018
09:19
25-07-18 Numis Add Target 380.00 Upgrade
7ran5ac710n
25/7/2018
10:30
Seems to be well supported, like the bounce off £2.60-£2.63in again
tsmith2
25/7/2018
10:02
Sold out here a week or so back. I don’t see anything really new to justify another 20% tumble in the stock.Its really about Sublocade going forward.If they can show in due course that their recent moves accelerate sales then the shares will recover.Its all too frenetic for me just now.......(that said I know I won’t be able to resist if they continue to hammer the stock like this!)
steeplejack
Chat Pages: 21  20  19  18  17  16  15  14  13  12  11  10  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180820 18:14:31